November 16, 2026
Breaking
Business

Biocon secures USFDA approval for Pebrilzo, its fifth cancer biosimilar

admin1 min read

Biocon also said it has secured a global settlement and licence agreement with Genentech, allowing Pebrilzo’s earliest licensed US launch in 2028.

The post Biocon secures USFDA approval for Pebrilzo, its fifth cancer biosimilar appeared first on Home Page.

Leave a Comment

Your email address will not be published. Required fields are marked *